Lumida
/FENC
⌘K
Fennec Pharmaceuticals Inc

Fennec Pharmaceuticals Inc

FENC
$10.96USD↓-3.01%-0.34 today

MARKET CAP

384.3M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$11 – $12

52W RANGE

$6
$13

AI Summary

Stalk
StalkMedium

FENC remains in a high-confidence Stage 2 advancing uptrend with an active momentum breakout confirming medium-term bullish structure, but price is currently extended above rising EMAs with overbought RSI and options score, making short-term execution unfavorable; deferred entries on a healthy pullback into support are advised.

  • ↑Q2 revenue rose 78% YoY to $17.1 M with net income of $1.97 M
  • ↑Non-GAAP EBITDA turned positive at $2.8 M vs a $1.2 M loss prior year
  • ↓Negative earnings yield and low book-to-price suggest overvaluation
Full analysis →

Buying

7

institutions

Selling

1

institutions

New Positions

4

this quarter

Filing Period

Q2 2026

latest 13-F

13-F Holdings

Institution↕Action↕Shares Held↕Value↓Change↕Chg %↕Weight↕
BI

Blackrock, Inc.

Q2 2026

BUY1.73 M18.57 M+358.89 K+120.7%0.00%
RT

Renaissance Technologies LLC

Q2 2026

BUYNEW134.20 K1.44 M+134.20 K+0.0%0.00%
AC

Aqr Capital Management LLC

Q2 2026

BUY92.89 K998.56 K+68.74 K+572.4%0.00%
CA

Citadel Advisors LLC

Q2 2026

SELL71.03 K763.59 K+-82.58 K-19.2%0.00%
PA

Point72 Asset Management, L.P.

Q2 2026

BUYNEW56.41 K606.38 K+56.41 K+0.0%0.00%
MM

Millennium Management LLC

Q2 2026

BUYNEW26.32 K282.91 K+26.32 K+0.0%0.00%
BH

Brevan Howard Capital Management LP

Q2 2026

BUYNEW21.47 K230.85 K+21.47 K+0.0%0.00%
JC

Jpmorgan Chase & Co

Q2 2026

BUY12.14 K133.94 K+284.00+95.7%0.00%